XML 30 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Operating activities      
Net loss $ (114,331) $ (23,364) $ (88,424)
Adjustments to reconcile net loss to net cash used for operating activities:      
Depreciation and amortization 4,146 3,961 3,779
Amortization of debt issuance costs and debt discount 65 3,142 7,909
Scilex Pharma Notes principal increase 0 0 28,000
Payment on the Scilex Pharma Notes attributed to accreted interest related to the debt discount 0 (21,190) (12,487)
(Gain) loss on debt extinguishment, net 0 (28,634) 12,463
Non-cash operating lease cost 507 492 372
Stock-based compensation 14,596 5,280 5,822
Issuance of shares under Settlement Agreement 750 0 0
Loss (gain) on derivative liability 512 (8,310) 300
Forfeitures of private warrants 0 1,697 0
Change in fair value of debt and liability instruments 7,189 0 0
Other 57 0 0
Changes in operating assets and liabilities:      
Accounts receivables, net (13,361) (6,968) (1,142)
Inventory (2,838) 1,184 (1,417)
Prepaid expenses and other (441) (2,629) 1,479
Other long-term assets 855 350 0
Accounts payable 19,880 2,806 (3,836)
Accrued Payroll 1,327 (2,379) (21)
Accrued expenses 2,310 (123) 664
Accrued rebates and fees 58,765 23,531 (255)
Other liabilities (711) (392) (80)
Related party payable 0 30,125 18,210
Other long-term liabilities 16 163 0
Net cash used for operating activities (20,707) (21,258) (28,664)
Investing activities      
Acquisition consideration paid in cash for Romeg intangible asset acquisition (300) (2,060) 0
Purchase of property, plant, and equipment (30) (7) 0
Net cash used for investing activities (330) (2,067) 0
Financing activities      
Proceeds from issuance of shares under Standby Equity Purchase Agreements 35,458 0 0
Proceeds from issuance of Convertible Debentures 24,000 0 0
Repayment of Convertible Debentures (15,625) 0 0
Proceeds from issuance of Revolving Facility 86,354 0 0
Repayment of Revolving Facility (69,001) 0 0
Repayment of Oramed Note (5,000) 0 0
Transaction costs paid related to the Business Combination (1,372) (2,949) 0
Payments of debt issuance costs (380) 0 0
Disbursement of funds to Sorrento (20,000) 0 0
Cash consideration paid in connection with share repurchase (10,000) 0 0
Transaction costs paid in connection with share repurchase (1,987) 0 0
Proceeds from the Business Combination 0 3,375 0
Proceeds from stock options and warrants exercised 1,135 96 0
Proceeds from related party payable 0 51,900 47,850
Proceeds from related party note payable 0 62,500 14,700
Proceeds from other loans 0 9,857 47,832
Repayment of principal on the Scilex Pharma Notes 0 (84,808) (33,387)
Repayment on other loans 0 (18,800) (48,832)
Net cash proceeds from financing activities 23,582 21,171 28,163
Net change in cash, cash equivalents and restricted cash 2,545 (2,154) (501)
Cash and cash equivalents at beginning of period 2,184 4,338 4,839
Cash and cash equivalents at end of period 4,729 2,184 4,338
Supplemental disclosure:      
Cash paid for interest 1,426 0 0
Supplemental disclosure of non-cash financing activity      
Issuance of shares to B.Riley pursuant to B. Riley Purchase Agreement 1,869 0 0
Conversion of Convertible Debentures into common stock 7,735 0 0
Right-of-use assets obtained in exchange for operating lease liabilities with lease modification 2,523 0 0
Oramed Note issuance at fair value 106,252 0 0
Other non-cash consideration in connection with share repurchase 26,154 0 0
Excise tax in connection with share repurchase included in accrued expenses 1,310 0 0
Related party debt converted to equity pursuant to Debt Exchange Agreement 0 289,733 0
Deferred consideration for Romeg intangible asset acquisition 0 3,650 0
Promissory Note issued to Sorrento in exchange for the SP-104 license 0 4,162 0
Fair value adjustment to derivative liability in troubled debt restructuring 0 30,400 0
Scilex Pharma Notes principal increase 0 0 28,000
Transaction costs obligation assumed by Sorrento $ 0 $ 5,148 $ 0